Judith Aberg

Summary

Affiliation: New York University
Country: USA

Publications

  1. ncbi request reprint A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087
    Judith A Aberg
    AIDS Clinical Trials Unit, Bellevue Hospital Center, New York University, New York, New York 10016, USA
    AIDS Res Hum Retroviruses 21:757-67. 2005
  2. pmc Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks
    Judith A Aberg
    Bellevue Hospital Center at New York University School of Medicine, New York, USA
    AIDS Res Hum Retroviruses 28:1184-95. 2012
  3. ncbi request reprint Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America
    Judith A Aberg
    AIDS Clinical Trials Unit, Bellevue Hospital Center, New York University, New York 10016, USA
    Clin Infect Dis 39:609-29. 2004
  4. pmc Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108
    Judith A Aberg
    New York University, New York, New York, USA
    AIDS 20:725-9. 2006
  5. pmc The virologic and immunologic effects of cyclosporine as an adjunct to antiretroviral therapy in patients treated during acute and early HIV-1 infection
    Martin Markowitz
    Aaron Diamond AIDS Research Center, an affiliate of Rockefeller University, New York, New York, USA
    J Infect Dis 201:1298-302. 2010
  6. ncbi request reprint Neuropsychiatric complications of antiretroviral therapy
    Michelle S Cespedes
    Division of Infectious Disease, Department of Medicine, New York University School of Medicine, New York, New York 10016, USA
    Drug Saf 29:865-74. 2006
  7. ncbi request reprint Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial
    Scott M Hammer
    Division of Infectious Diseases, Department of Medicien, Columbia University College of Physicians and Surgeons, 630 W 168th St, New York, NY 10032, USA
    JAMA 288:169-80. 2002
  8. pmc Lipid management in patients who have HIV and are receiving HIV therapy
    Judith A Aberg
    Bellevue Hospital Center, AIDS Clinical Trials Unit, New York University School of Medicine, 550 First Avenue, BCD 5 Room 558, NY 10016, USA
    Endocrinol Metab Clin North Am 38:207-22. 2009
  9. ncbi request reprint Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers
    Marshall J Glesby
    Weill Medical College of Cornell University, New York, NY 10021, USA
    Clin Pharmacol Ther 78:143-53. 2005
  10. pmc Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: five-year outcomes
    Douglas A Jabs
    Department of Ophthalmology, The Mount Sinai School of Medicine, New York, New York, USA
    Ophthalmology 117:2152-61.e1-2. 2010

Research Grants

Detail Information

Publications43

  1. ncbi request reprint A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087
    Judith A Aberg
    AIDS Clinical Trials Unit, Bellevue Hospital Center, New York University, New York, New York 10016, USA
    AIDS Res Hum Retroviruses 21:757-67. 2005
    ..Combination therapy with fenofibrate and pravastatin for HIV-related dyslipidemia provides substantial improvements in lipid parameters and appears safe, but is unlikely to achieve all NCEP targets for lipid levels...
  2. pmc Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks
    Judith A Aberg
    Bellevue Hospital Center at New York University School of Medicine, New York, USA
    AIDS Res Hum Retroviruses 28:1184-95. 2012
    ..This first pilot comparison in HIV-1-infected subjects suggests that DRV/r has a metabolic profile similar to ATV/r over 48 weeks of treatment. Further randomized studies are warranted...
  3. ncbi request reprint Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America
    Judith A Aberg
    AIDS Clinical Trials Unit, Bellevue Hospital Center, New York University, New York 10016, USA
    Clin Infect Dis 39:609-29. 2004
  4. pmc Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108
    Judith A Aberg
    New York University, New York, New York, USA
    AIDS 20:725-9. 2006
    ..Nelfinavir, an HIV protease inhibitor with numerous drug-drug interactions, is associated with dyslipidemia. Pravastatin is the preferred statin prescribed for HIV-associated dyslipidemia...
  5. pmc The virologic and immunologic effects of cyclosporine as an adjunct to antiretroviral therapy in patients treated during acute and early HIV-1 infection
    Martin Markowitz
    Aaron Diamond AIDS Research Center, an affiliate of Rockefeller University, New York, New York, USA
    J Infect Dis 201:1298-302. 2010
    ..Adjunctive therapy with cyclosporine in this setting does not provide apparent virologic or immunologic benefit...
  6. ncbi request reprint Neuropsychiatric complications of antiretroviral therapy
    Michelle S Cespedes
    Division of Infectious Disease, Department of Medicine, New York University School of Medicine, New York, New York 10016, USA
    Drug Saf 29:865-74. 2006
    ..Our intent is to present practitioners with data that can be used in a practical way to both educate and improve outcomes in the HIV-infected patient population...
  7. ncbi request reprint Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial
    Scott M Hammer
    Division of Infectious Diseases, Department of Medicien, Columbia University College of Physicians and Surgeons, 630 W 168th St, New York, NY 10032, USA
    JAMA 288:169-80. 2002
    ..Management of antiretroviral treatment failure in patients receiving protease inhibitor (PI)-containing regimens is a therapeutic challenge...
  8. pmc Lipid management in patients who have HIV and are receiving HIV therapy
    Judith A Aberg
    Bellevue Hospital Center, AIDS Clinical Trials Unit, New York University School of Medicine, 550 First Avenue, BCD 5 Room 558, NY 10016, USA
    Endocrinol Metab Clin North Am 38:207-22. 2009
    ..Evidence for these two strategies is discussed...
  9. ncbi request reprint Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers
    Marshall J Glesby
    Weill Medical College of Cornell University, New York, NY 10021, USA
    Clin Pharmacol Ther 78:143-53. 2005
    ..We evaluated potential bidirectional pharmacokinetic interactions between calcium channel blockers and coadministered indinavir and ritonavir...
  10. pmc Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: five-year outcomes
    Douglas A Jabs
    Department of Ophthalmology, The Mount Sinai School of Medicine, New York, New York, USA
    Ophthalmology 117:2152-61.e1-2. 2010
    ..To describe the 5-year outcomes of patients with cytomegalovirus (CMV) retinitis and AIDS in the era of highly active antiretroviral therapy (HAART)...
  11. doi request reprint Implementation of HIV testing at 2 New York City bathhouses: from pilot to clinical service
    Demetre Daskalakis
    Division of Infectious Diseases and Immunology, New York University Langone Medical Center, New York, New York 10016, USA
    Clin Infect Dis 48:1609-16. 2009
    ..Several cities in the United States have developed programs that offer HIV testing in these venues. Similar programs have not existed before in New York City...
  12. ncbi request reprint Pafuramidine for Pneumocystis jiroveci pneumonia in HIV-infected individuals
    Donald Chen
    New York University, Department of Medicine, Division of Infectious Disease, AIDS Clinical Trials Unit, Bellevue C and D Building, Room 558, 550 First Avenue, New York, NY 10016 6481, USA
    Expert Rev Anti Infect Ther 5:921-8. 2007
    ..To date, human trials suggest that pafuramidine is well tolerated overall and has clinical activity against Pneumocystis pneumonia. In this article, we review the available data for the use of pafuramidine in Pneumocystis pneumonia...
  13. doi request reprint Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America
    Judith A Aberg
    New York University School of Medicine, Bellevue Hospital Center, New York, USA
    Clin Infect Dis 49:651-81. 2009
    ..HIV-infected persons should be managed and monitored for all relevant age- and gender-specific health problems. New information based on publications from the period 2003-2008 has been incorporated into this document...
  14. pmc Cardiovascular complications in HIV management: past, present, and future
    Judith A Aberg
    AIDS Clinical Trials Unit, Bellevue Hospital Center, New York University School of Medicine, New York, NY 10016, USA
    J Acquir Immune Defic Syndr 50:54-64. 2009
    ..These benefits of antiretroviral therapy have been demonstrated in studies comparing the superior efficacy of continuous vs. intermittent HAART...
  15. pmc A tale of two fungi in a person with HIV
    Jason Faulhaber
    Division of Infectious Diseases and Immunology, New York University School of Medicine, New York, NY, USA
    MedGenMed 8:2. 2006
  16. ncbi request reprint Drug-drug interactions with newer antiretroviral agents
    Judith A Aberg
    New York University School of Medicine and Bellevue Hospital Center, New York, NY, USA
    Top HIV Med 16:146-50. 2008
    ....
  17. ncbi request reprint Localized osteomyelitis due to Mycobacterium avium complex in patients with Human Immunodeficiency Virus receiving highly active antiretroviral therapy
    Judith A Aberg
    Department of Medicine, Washington University School of Medicine, AIDS Clinical Trials Unit, St Louis, MO, 63108, USA
    Clin Infect Dis 35:E8-E13. 2002
    ..The low rate of these unusual MAC infections does not warrant continuation of primary or secondary prophylaxis after presumed immune reconstitution...
  18. ncbi request reprint A case of nocardia osteomyelits--is HIV to blame?
    Judith A Aberg
    Washington University, AIDS Clinical Trials Unit, St Louis, USA
    AIDS Read 12:77. 2002
  19. doi request reprint Coronary heart disease in people infected with HIV
    Carlos D Malvestutto
    New York University Langone Medical Center, New York, USA
    Cleve Clin J Med 77:547-56. 2010
    ..As this population ages, cardiovascular disease is becoming an important cause of morbidity and death. The authors of this review discuss the magnitude and likely mechanisms of the risk and strategies for managing it...
  20. pmc Case files from the Bellevue Hospital Center at New York University--lipoatrophy following long-term antiretroviral therapy
    Demetre Daskalakis
    Division of Infectious Disease and Immunology, Department of Medicine, New York University School of Medicine Bellevue Hospital, New York, NY, USA
    MedGenMed 7:9. 2005
  21. ncbi request reprint Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047
    Carl J Fichtenbaum
    University of Cincinnati College of Medicine, Holmes Hospital, Eden Avenue and Albert Sabin Way, Cincinnati, Ohio 45267 0405, USA
    AIDS 16:569-77. 2002
    ....
  22. pmc Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186
    John G Gerber
    Department of Medicine, University of Colorado Health Sciences Center, Denver, CO, USA
    J Acquir Immune Defic Syndr 47:459-66. 2008
    ..AIDS Clinical Trials Group A5186 examined the safety and efficacy of fish oil plus fenofibrate in subjects not achieving serum TG levels < or =200 mg/dL with either agent alone...
  23. pmc Comparison of direct and indirect measurement of LDL-C in HIV-infected individuals: ACTG 5087
    Scott R Evans
    Harvard School of Public Health, Boston, MA, USA
    HIV Clin Trials 8:45-52. 2007
    ..Triglyceride (TG) levels >400 mg/dL interfere with the accurate determination of low-density lipoproteins (LDL-C) by the Friedewald equation, making it difficult to assess coronary heart disease risk...
  24. ncbi request reprint Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial
    Donald I Abrams
    University of California, San Francisco, and Gladstone Institute of Virology and Immunology, San Francisco, California 94110, USA
    Ann Intern Med 139:258-66. 2003
    ..Cannabinoid use could potentially alter HIV RNA levels by two mechanisms: immune modulation or cannabinoid-protease inhibitor interactions (because both share cytochrome P-450 metabolic pathways)...
  25. ncbi request reprint Management of dyslipidemia and other cardiovascular risk factors in HIV-infected patients: case-based review
    Judith A Aberg
    Department of Medicine, New York University Medical Center, USA
    Top HIV Med 14:134-9. 2006
    ..The article is based on a presentation on management of dyslipidemia and other cardiovascular risk factors in HIV infection made by Judith A. Aberg, MD, at the International AIDS Society-USA Los Angeles CME program in February 2006...
  26. ncbi request reprint Nonnucleoside reverse transcriptase inhibitor resistance among antiretroviral-naive HIV-positive pregnant women
    Salome N Juethner
    Division of Infectious Diseases, Washington University School of Medicine, St Louis, Missouri 63108, USA
    J Acquir Immune Defic Syndr 32:153-6. 2003
    ....
  27. ncbi request reprint Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study
    John G Gerber
    University of Colorado Health Sciences Center, Denver, CO 80262, USA
    J Acquir Immune Defic Syndr 39:307-12. 2005
    ..The reduced inhibition of HMG-CoA reductase activity during coadministration of EFV may result in diminished antilipid efficacy at usual doses of SIM, ATR, and PRA...
  28. ncbi request reprint Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors
    Carla B Washington
    Department of Medicine, Stanford University Medical Center, Stanford, CA 94305 5130, USA
    Clin Pharmacol Ther 73:406-16. 2003
    ..The aim of this study was to determine whether pharmacokinetic interactions between the protease inhibitors saquinavir soft gel, nelfinavir, and ritonavir are affected by the timing of administration...
  29. ncbi request reprint Cardiovascular risk among HIV-positive patients on antiretroviral therapy
    Judith A Aberg
    Division of Infectious Diseases School of Medicine, Washington University, St Louis, Missouri, USA
    J Int Assoc Physicians AIDS Care (Chic) 2:S24-39. 2003
    ..The fundamental message still is that physicians must treat HIV infection first. The choice of ART depends on many patient-specific factors, of which cardiovascular risk is only one...
  30. ncbi request reprint Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study
    Cristina Mussini
    Clinic of Infectious and Tropical Diseases, University of Modena and Reggio Emilia, Azienda Policlinico, Modena, Italy
    Clin Infect Dis 38:565-71. 2004
    ..Recurrent cryptococcal infection should be suspected in patients whose serum cryptococcal antigen test results revert back to positive after discontinuation of maintenance therapy...
  31. ncbi request reprint Cure of acute hepatitis C in HIV co-infection?
    Maria B Ristig
    J Clin Gastroenterol 38:303. 2004
  32. ncbi request reprint Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy
    Mitchell Goldman
    Division of Infectious Diseases, Indiana University School of Medicine, Wishard Memorial Hospital, Indianapolis, Indiana 46202, USA
    Clin Infect Dis 38:1485-9. 2004
    ....
  33. ncbi request reprint Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed
    Maria B Ristig
    Division of Infectious Diseases, Washington University School of Medicine, St Louis, Missouri 63108, USA
    J Infect Dis 186:1844-7. 2002
    ..There was a transient increase of transaminases after the initiation of treatment. No patient developed HBe antibodies. TDF is a very promising drug for the treatment of chronic hepatitis B in HIV-infected individuals...
  34. ncbi request reprint Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult
    Michael P Dube
    Indiana University, Indianapolis, USA
    Clin Infect Dis 37:613-27. 2003
  35. pmc Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis
    Robert A Larsen
    Department of Medicine Infectious Diseases, 2020 Zonal Ave, IRD Room 632, MC 9520, University of Southern California, Los Angeles, CA 90033, USA
    Antimicrob Agents Chemother 49:952-8. 2005
    ..The half-life of MAb 18B7 in serum was approximately 53 h, while the MAb was undetectable in the cerebrospinal fluid of all patients. These data support the continued investigation of MAb 18B7 at a maximum single dose of 1.0 mg/kg...
  36. ncbi request reprint A study of discontinuing maintenance therapy in human immunodeficiency virus-infected subjects with disseminated Mycobacterium avium complex: AIDS Clinical Trial Group 393 Study Team
    Judith A Aberg
    Department of Medicine, Division of Infectious Disease, University of California San Francisco, San Francisco, CA, USA
    J Infect Dis 187:1046-52. 2003
    ..44/100 person-years (95% confidence interval, 0.04-8.01). Withdrawal of anti-MAC therapy appears to be safe in patients who have been treated with a macrolide-based regimen for at least 1 year and have an immunologic response on HAART...
  37. doi request reprint Clinical impact of patient population differences and genomic variation in efavirenz therapy
    Jennifer King
    AIDS 22:1709-17. 2008
    ....
  38. pmc Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding
    Jacob P Lalezari
    Quest Clinical Research, San Francisco, California, USA
    Antimicrob Agents Chemother 46:2969-76. 2002
    ..9 to 3.7 log(10) PFU/ml among the four regimens evaluated for anti-HCMV activity. 1263W94 was generally well tolerated; taste disturbance was the most frequently reported adverse event over the 28-day dosing period...
  39. ncbi request reprint Tolerance of efavirenz-induced central nervous system side effects in HIV-infected individuals with a history of substance abuse
    Salome N Juethner
    Division of Infectious Disease, Washington University School of Medicine, St Louis, Missouri 63108, USA
    HIV Clin Trials 4:145-9. 2003
    ....
  40. ncbi request reprint Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons
    Edgar Turner Overton
    Washington University School of Medicine, St Louis, MO 63110, USA
    Clin Infect Dis 41:1045-8. 2005
    ..5%) developed a protective antibody response. In a logistic regression model, only a plasma HIV RNA level of <400 copies/mL at the time of vaccination was associated with a protective antibody response (P=.003)...
  41. pmc Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148
    Michael P Dube
    Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA
    Antivir Ther 11:1081-9. 2006
    ..Dyslipidaemia is very common in patients with HIV infection, but current therapies are often suboptimal. Since niacin may cause insulin resistance and hepatotoxicity, it has generally been avoided in this setting...
  42. ncbi request reprint Dyslipidemia in HIV patients
    Marisa Tungsiripat
    Department of Infectious Diseases, The Cleveland Clinic Foundation, OH 44195, USA
    Cleve Clin J Med 72:1113-20. 2005
    ..Interactions between lipid-lowering drugs and antiretroviral drugs require special attention...
  43. ncbi request reprint Discontinuation of antiretroviral therapy postpartum: no evidence for altered viral set point
    Marisa Tungsiripat
    J Acquir Immune Defic Syndr 44:116-7. 2007

Research Grants2

  1. New York University HIV/AIDS Clinical Trial Unit
    Judith Aberg; Fiscal Year: 2007
    ..Our unit has given significant scientific contributions to the concept and design of many studies and will continue to do so. ADMINISTRATIVE COMPONENT: ..